Keith Chong, PhD, MBA, is a virologist and entrepreneur with 7 years of research on the dengue virus. He spent 8 years at Merck as APAC Regional Marketing Manager before founding a company to commercialize a dengue prognostic kit. The COVID-19 pandemic led him to join Creative Medtech Solutions Pte Ltd and co-found UroMedtech Pte Ltd, where he now serves as Managing Director, overseeing product development, regulatory strategy, commercialization, and fundraising.
Virology, Urology, Oncology, Robotic, AI
Uromaster Is The Machine I Built On AI For Prostate Cancer Detection
Prostate cancer remains one of the most prevalent cancers in men, with early detection being crucial for effective treatment. UroMaster Adventure is an advanced prostate biopsy system designed to enhance accuracy, efficiency, and patient comfort. A key feature of UroMaster Adventure is its AI-powered auto-segmentation technology, which automates prostate contouring during biopsy procedures. This innovation significantly reduces the time required for segmentation by at least 5–10 minutes, streamlining the workflow for clinicians while maintaining high precision. In this seminar, we will review the latest advancements in prostate biopsy techniques and explore the role of AI in transforming the landscape of prostate cancer diagnosis. AI-driven automation not only improves procedural accuracy but also increases accessibility by reducing operator dependency, enhancing productivity, and optimizing resource utilization. Furthermore, improved workflow efficiency translates to a more comfortable experience for patients, minimizing procedure duration and potential discomfort. As AI continues to advance, its integration into prostate biopsy procedures will enable faster, more reliable diagnoses and better clinical outcomes.